Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
P649071-5mg | 5mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $480.90 | |
P649071-10mg | 10mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $800.90 | |
P649071-25mg | 25mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $1,700.90 | |
P649071-50mg | 50mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $2,800.90 | |
P649071-100mg | 100mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $4,300.90 |
Synonyms | 2-Oxazolidinone, 5-[[4-(1,3-benzodioxol-5-yl)-4-hydroxy-1-piperidinyl]methyl]-3-(4-methoxyphenyl)-, (5S)- | Panamesine | Panamesine [INN] | Q27231486 | (5S)-5-[[4-(1,3-benzodioxol-5-yl)-4-hydroxypiperidin-1-yl]methyl]-3-(4-methoxyphenyl)-1,3-oxazolidin-2- |
---|---|
Specifications & Purity | ≥99% |
Biochemical and Physiological Mechanisms | Panamesine (EMD 57445) is a sigma receptor ligand, which has a high affinity ( IC 50 6 nM) and selectivity for sigma binding sites. Panamesine is a potential atypical neuroleptic agent. |
Storage Temp | Store at -20°C |
Shipped In | Ice chest + Ice pads |
Product Description | Panamesine (EMD 57445) is a sigma receptor ligand, which has a high affinity ( IC 50 6 nM) and selectivity for sigma binding sites. Panamesine is a potential atypical neuroleptic agent In Vivo Panamesine (EMD 57445; 0.3, 1, 3, 30 mg/kg) induces a dose-dependent increase of c-fos expression in several cortical areas with the strongest signals in the piriform cortex . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Female Sprague Dawley rats aged 2 months with a body weights of 200-250 g Dosage: 0.3, 1, 3, 30 mg/kg Administration: Subcutanous injections Result: Specific c-fos gene expression was detected at all concentrations (0.3 mg/kg, 1 mg/kg, 3 mg/kg, 30 mg/kg) tested in frontal, parietal, perirhinal, temporal, piriform, insular, limbic, cingulate and occipital cortex. Form:Solid IC50& Target:IC50: 6 nM (sigma receptor) |
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
IUPAC Name | (5S)-5-[[4-(1,3-benzodioxol-5-yl)-4-hydroxypiperidin-1-yl]methyl]-3-(4-methoxyphenyl)-1,3-oxazolidin-2-one |
---|---|
INCHI | InChI=1S/C23H26N2O6/c1-28-18-5-3-17(4-6-18)25-14-19(31-22(25)26)13-24-10-8-23(27,9-11-24)16-2-7-20-21(12-16)30-15-29-20/h2-7,12,19,27H,8-11,13-15H2,1H3/t19-/m0/s1 |
InChi Key | NINYZUDVKTUKIA-IBGZPJMESA-N |
Canonical SMILES | COC1=CC=C(C=C1)N2CC(OC2=O)CN3CCC(CC3)(C4=CC5=C(C=C4)OCO5)O |
Isomeric SMILES | COC1=CC=C(C=C1)N2C[C@@H](OC2=O)CN3CCC(CC3)(C4=CC5=C(C=C4)OCO5)O |
Alternate CAS | 139225-22-2 |
PubChem CID | 3047810 |
MeSH Entry Terms | (5S)-5-((4-Hydroxy-4-(3,4-(methylenedioxy)phenyl)piperidino)methyl)-3-(p-methoxyphenyl)-2-oxazolidinone;5-(4-hydroxy-4-(1,3-benzodioxol-5-yl)piperidine-1-ylmethyl)-3-(4-methoxyphenyl)oxazolidine-2-one hydrochloride;EMD 57445;EMD-57445;panamesine |
Molecular Weight | 426.46 |
Solubility | DMSO : 125 mg/mL (293.11 mM; Need ultrasonic) |
---|